Biochemical characterization of a novel Fragile X Mental Retardation Protein nuclease function

  • Funded by National Institutes of Health (NIH)
  • Total publications:2 publications

Grant number: 2R15GM127307-05

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2005
    2024
  • Known Financial Commitments (USD)

    $414,000
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Mihaela R Mihailescu
  • Research Location

    United States of America
  • Lead Research Institution

    N/A
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary Fragile X mental retardation syndrome is the most common form of inherited mental impairement, affecting ~ 1 in 4000 males and ~ 1 in 6000 females. The syndrome is caused by the loss of a normal cellular protein, named the fragile X mental retardation protein (FMRP). FMRP is an RNA binding protein involved in the transport and translation regulation of specific messenger RNA (mRNA) targets. The mechanisms by which FMRP exerts its translation regulator function are not known, however it has been proposed that the protein works in conjunction with the microRNA (miRNA) pathway to regulate local protein synthesis in response to synaptic input. We have determined that FMRP has nuclease activity, being able to process precursor microRNAs (pre-miRNAs), potentially being involved in the mature miRNA biogenesis. This proposal, which will characterize this novel FMRP function, has the following specific aims: AIM I. Identification of the FMRP domain(s) responsible for its nuclease activity. We hypothesized that the FMRP nuclease activity resides in one of his K homology domains and to test this hypothesis we will produce several FMRP constructs lacking one or more of these domains. We determined that phosphorylated FMRP has higher nuclease efficiency than the unphosphorylated FMRP and we will test if this is caused by their different dimerization properties. Finally, we will also test if the FMRP paralogs, FXR1P and FXR2P, which share with FMRP the KH0, KH1 and KH2 domains, also have nuclease activity. AIM II. Biochemical characterization of the FMRP nuclease activity. We will determine if the pre-miRNA FMRP and its phosphorylated mimic can cleave pre-miRNAs into mature miRNAs. Additionally, we will determine if FMRP has additional substrates for its nuclease activity such as RNA perfect duplex, RNA single strand, RNA G quadruplex, DNA-RNA hybrid duplex, DNA duplex. Finally, we will characterize the kinetics of the FMRP nuclease. AIM III. Investigation of the FMRP interactions with the SARS-CoV-2 3'-UTR genome and of the potential role played by its nuclease activity in this viral system. Similar to its demonstrated role of restrictive factor in ZIKA virus infection, it has been proposed that FMRP might play a role in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for the current COVID-19 pandemic. We will test if FMRP cleaves various stem-loops within the SARS-CoV-2 RNA genomic 3'-untranslated region using its nuclease function either to potentially yield viral miRNAs or functioning in the antiviral host response.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Effect of the SARS-CoV-2 Delta-associated G15U mutation on the s2m element dimerization and its interactions with miR-1307-3p.

Uridylation of the histone mRNA stem-loop weakens binding interactions with SLBP while maintaining interactions with 3'hExo.